Education:
1982-1984 Premedical Course, Tokushima University Faculty of Medicine, Tokushima, Japan
1984-1988 Medical Course, Tokushima University Faculty of Medicine, Tokushima, Japan
1988 M.D., Tokushima University and Medical License 1989-1993 Graduate School, Tokushima University Faculty of Medicine
1993 Ph.D. in medical science, Tokushima University
Position:
1993-1995 Resident, Third Department of Internal Medicine, University of Tokushima School of Medicine
1995-1999 Research Associate, Third Department of Internal Medicine, University of Tokushima School of Medicine
1996-1998 Research Fellow, Departments of Surgery and Molecular Genetics and Biochemistry, Pittsburgh University, PA, U.S.A.
1999-2002 Assistant Professor, Third Department of Internal Medicine, University of Tokushima School of Medicine
2002-2004 Assistant Professor, Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine
2004-2007 Assistant Professor, Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, University of Tokushima Graduate School
2007-2008 Associate Professor, Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, University of Tokushima Graduate School
2008-2011 Associate Professor, Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School
2008 July-Oct Visiting associate professor, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, TX, U.S.A.
2011-2014 Professor and Chairman, Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School
2015-2016 Professor and Chairman, Department of Respiratory Medicine and Rheumatology, Institute of Biomedical Sciences, Tokushima University Graduate School
2016-present Professor and Chairman, Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University
2019-present Professor and Chairman, Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University
2019-2022 Vice director of Tokushima University Hospital
2022-2024 Dean, Graduate School of Medicine, Tokushima University
Vice-Dean, Graduate School of Biomedical Sciences, Tokushima University
Dean, Faculty of Medicine, Tokushima University
2026-present Dean, Graduate School of Biomedical Sciences, Tokushima University
Vice Director for Regional Collaboration, Tokushima University
Job Title
Professor and Chairman
Faculty / Department / Division
Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences
Institution / Organisation
Tokushima University
20 November 2026, Friday
| Time |
Session |
|
|
09:30
11:00
|
-
-
Interstitial lung abnormalities (ILAs) are chest CT findings suggestive of interstitial lung disease (ILD) in people without a clinical diagnosis of ILD. With lung cancer screening and the wide use of CT, they are increasingly encountered in respiratory practice. The 2025 American Thoracic Society (ATS) clinical statement updated the 2020 Fleischner Society definition: ILA is now defined as bilateral, nondependent ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, or honeycombing involving at least 5% of a lung zone, without the requirement that the findings be incidental, and with high-risk groups such as familial pulmonary fibrosis and connective tissue disease included. A working definition separates ILA from ILD on the basis of symptoms, physiology, imaging, and pathology.
ILA is found in about 3–10% of older adults and 4–17% of smokers. Risk factors include older age, male sex, smoking, occupational and environmental exposures, the MUC5B promoter variant, short telomeres, and a family history of pulmonary fibrosis. ILA is associated with respiratory symptoms, reduced exercise capacity, lung cancer, complications of cancer treatment and surgery, acute respiratory distress syndrome, and all-cause mortality. About half of ILAs progress radiologically, and subpleural fibrotic ILA, reticulation, and traction bronchiectasis carry the highest risk of progression and death.
Based on 11 questions, the ATS statement suggests systematic assessment of ILA on lung cancer screening CT, baseline CT for adults with connective tissue disease at risk of ILD and for first-degree relatives older than 50 years in familial pulmonary fibrosis, assessment of symptoms and lung function at baseline, and serial CT timed by risk; it suggests against lung biopsy and routine MUC5B or telomere testing. Risk reduction, including smoking cessation and exposure remediation, is recommended throughout. No pharmacological treatment is currently recommended for ILA, but prevention trials with better-tolerated antifibrotics, such as DROP-FPF with nerandomilast, have begun. This lecture reviews the definition, epidemiology, clinical significance, risk assessment, and management of ILA, with data from Korean cohorts.
-
-
Ballroom 4, Lower Ground Floor
|
21 November 2026, Saturday
| Time |
Session |
|
|
09:00
09:30
|
Translational Research on the Development of Antifibrotic Drugs for Pulmonary Fibrosis and Lung Cancer
Ballroom 3, Lower Ground Floor
|